Infectious Diseases News and Research

RSS

Pediatric transplant recipients mount a more robust immune response after two COVID-19 vaccine doses

In a study published today in the American Journal of Transplantation, Johns Hopkins Medicine researchers say that children between the ages of 12 and 18 who have received solid organ transplants appear to mount a more robust immune response than their adult counterparts after a standard two-dose vaccination regimen against SARS-CoV-2, the virus that causes COVID-19.

30 Sep 2021

Rise of the Delta variant increases COVID-19 hospitalizations among unvaccinated pregnant women

Unvaccinated pregnant women are increasingly being hospitalized with COVID-19 during a nationwide surge of the Delta variant, according to research from UT Southwestern Medical Center.

30 Sep 2021

Research points the way to identifying new precision treatments for cancer

Researchers at University of California San Diego and University of California San Francisco have mapped out how hundreds of mutations involved in two types of cancer affect the activity of discrete groups of proteins that are the ultimate actors behind the disease.

30 Sep 2021

Government sets additional funding for infection prevention and control in social care settings

People who receive care and the adult social care workforce will be further protected from COVID-19 and flu over the coming months, as the government sets additional funding for infection prevention and control.

30 Sep 2021

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that Teresa H. Evering, M.D., M.S., a co-lead investigator (with Eric S. Daar, M.D.) for BRII-196/BRII-198 in the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies, will present data for the monoclonal antibody combination at the virtual IDWeek 2021 conference, taking place September 29 – October 3, 2021.

30 Sep 2021

Research gauges reductions in the quality of life during COVID-19

The results of a survey were published on the medRxiv* preprint server, the purpose of which was to assess the relative well-being of the population under Covid-19 restrictions – through 952 survey respondents from France, India, Italy, the UK, and the US.

29 Sep 2021

Columbia University and partners launch and operate New York City's first Pandemic Response Institute

Through a groundbreaking new award from New York City Economic Development Corporation (NYCEDC), Columbia University – through its Mailman School of Public Health – and a consortium of academic, community, government, and corporate partners will launch and operate New York City's first Pandemic Response Institute (PRI).

29 Sep 2021

Universal screening for SARS-CoV-2 among hospitalized patients may be ineffective

Universal screening of all hospital admissions for infection with SARS-CoV-2 is highly inefficient as a screening method in regions with a low prevalence of COVID-19 in the absence of high-risk factors.

29 Sep 2021

Machine learning may predict zoonotic potential of viral genomes

Most emerging infectious diseases of humans (like COVID-19) are zoonotic – caused by viruses originating from other animal species. Identifying high-risk viruses earlier can improve research and surveillance priorities.

28 Sep 2021

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded approximately $36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants.

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

COVID Moonshot receives key funding to accelerate drug discovery efforts

The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.

28 Sep 2021

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

A version of SARS-CoV-2, the virus that causes COVID-19 disease, has been successfully modified to glow brightly in cells and animal tissues, providing a real-time way to track the spread and intensity of viral infection as it happens in animal models, researchers at Texas Biomedical Research Institute report in the journal The Proceedings of the National Academy of Sciences.

27 Sep 2021

NYU wins roughly $4 million federal grant to protect transit workers from COVID-19

NYU School of Global Public Health researchers have been awarded a five-year, roughly $4 million grant from the National Institutes of Health to study efforts to protect New York City transit workers from COVID-19 and how these infection prevention and control programs impact the health and well-being of frontline workers.

27 Sep 2021

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

A team from the National Institute for Infectious Diseases “L. Spallanzani” (INMI) has recently reported their study on 94 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (47.9% symptomatic, 52.1% asymptomatic) that occurred after the first or second vaccine dose against SARS-CoV-2 in the Lazio region (Central Italy).

27 Sep 2021

SARS-CoV-2 infection less severe in children and youth during first part of the pandemic

New research has found that children and youth may be at low risk of severe acute COVID-19, according to a study conducted during the first half of the pandemic and published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.210053.

27 Sep 2021

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Japanese scientists created "elite" antibodies that defeat various coronavirus variants even at an extremely low dose through a new method that accelerated the months-long process of finding such extraordinary antibody candidates to just ten days.

27 Sep 2021

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

25 Sep 2021

Penn scientists win 2021 Lasker Award for the discovery of therapeutic mRNA technology

As mRNA-based SARS-CoV-2 vaccines are deployed to protect hundreds of millions of people across the world and point the way to end the deadly global COVID-19 pandemic, the University of Pennsylvania scientists whose prescient discovery science effort laid the foundation for swift vaccine development have been awarded the 2021 Lasker~DeBakey Clinical Medical Research Award.

24 Sep 2021

Further evidence of safety and efficacy of mRNA-1273 vaccine in preventing symptomatic COVID-19 and SARS-CoV-2 infection

A recent study supports the efficacy of the mRNA-1273 vaccine in preventing COVID-19 illness and disease severity.

24 Sep 2021

Infectious Diseases News and Research

Pediatric transplant recipients mount a more robust immune response after two COVID-19 vaccine doses

Rise of the Delta variant increases COVID-19 hospitalizations among unvaccinated pregnant women

Research points the way to identifying new precision treatments for cancer

Government sets additional funding for infection prevention and control in social care settings

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

Research gauges reductions in the quality of life during COVID-19

Columbia University and partners launch and operate New York City's first Pandemic Response Institute

Universal screening for SARS-CoV-2 among hospitalized patients may be ineffective

Machine learning may predict zoonotic potential of viral genomes

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

COVID Moonshot receives key funding to accelerate drug discovery efforts

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

NYU wins roughly $4 million federal grant to protect transit workers from COVID-19

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

SARS-CoV-2 infection less severe in children and youth during first part of the pandemic

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Penn scientists win 2021 Lasker Award for the discovery of therapeutic mRNA technology

Further evidence of safety and efficacy of mRNA-1273 vaccine in preventing symptomatic COVID-19 and SARS-CoV-2 infection

Industry Focus: Infectious Diseases eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News